Good Pharmaceutical Development Company
Dr. Larry Good has been a practicing gastroenterologist since 1978. Dr. Good graduated Colgate University Magna Cum Laude in 1969 and received his M.D. with Alpha Omega Alpha status from the Medical University of South Carolina in Charleston, SC in 1973.
Dr. Good served a medical residency from 1973-76 and was Chief Medical Resident in 1976. He was fellowship trained in gastroenterology from 1976-78.
Dr. Good has served as the Director of Liver Diseases at Nassau County Medical Center and was for many years Chief, Division of Gastroenterology, Department of Medicine at South Nassau Communities Hospital. Dr. Good is an assistant clinical professor of medicine at SUNY Stony Brook. He has given hundreds of lectures in his field and has authored numerous papers and abstracts. Recently, Dr. Good presented the ACG Theater lecture at the American College of Gastroenterology annual meeting in Chicago, Illinois in October, 2014.
Dr. Good was Chief Medical Officer at Ritter Pharmaceuticals in Los Angeles, California, where he expanded his research interest in the intestinal microbiome. Dr. Good’s current clinical research activities involve the microbiome, inflammatory bowel disease, irritable bowel syndrome and the application of orally administered gamma globulin to patients with acute and chronic gastro-intestinal disorders.
Dr. Good founded Good Pharmaceutical Development Co., LLC, in 2014. He is their CEO and is developing a topical product for treating neuropathic pain. Dr. Good was recently appointed CEO of Compassionate Care Center of New York, a company founded to provide medical marijuana product safely and affordably to residents of New York State adhering to the evolving NYS regulations and producing a pharmaceutical grade treatment option for specific diagnosis designated use.
Dr. Good was appointed as an editor of BMC Gastroenterology, a prestigious on line peer reviewed medical journal. He is a member of the Speakers Bureau for Entera Health, Abbvie and Cubist Pharmaceuticals.
Dr. Good currently receives research grants from Entera Health and Medicus Biosciences.
Dr. Good is the former C.E.O. of Compassionate Care Center of NY and has had a long interest in research application of the physiology of natural molecules to multiple disease states.
Currently, Dr. Good is the C.E.O. of New Century Health Alliance, L.L.C., a Continuing Medical Education Company certified to provide 6.25 AMA PRA credits for education in the area of medical marijuana treatment.
In May, 2016, Dr. Good was named to the Steering Committee for Medical Marijuana Research and Education Division, Department of Integrated Medicine at Thomas Jefferson Medical University in Philadelphia. He has just completed a manuscript soon to be published on the treatment of Crohn’s Disease and Ulcerative Colitis with medical marijuana pharmaceuticals.
Gastroenterology, Crohn’s Disease and Ulcerative Colitis